Graduates from NYU Stern's top accelerator, Stimvia, sets sights on the U.S market, aiming to introduce bladder therapy device
In the world of MedTech innovation, Stimvia, a Czech Republic-based company, has made a significant stride, graduating from the prestigious Endless Frontier Labs program at NYU Stern School of Business. This news was not covered in the recent article discussing global initiatives to change wearable medical device market trends featured in "Digital Health & AI Insights".
Stimvia's focus lies in developing the URIS system, a non-invasive neuromodulation device designed to treat Overactive Bladder (OAB) without the need for surgery or drugs. The URIS system employs Stimvia's proprietary eTNM (peroneal transcutaneous electrical nerve stimulation) method to deliver targeted neurostimulation.
The Overactive Bladder treatment market, particularly in the US, is a significant and rapidly growing sector, driven by an aging population and increased awareness and diagnosis. Estimates place the US OAB market size in the range of several hundred million to over a billion US dollars annually, encompassing devices, pharmaceuticals, and combination therapies.
Stimvia's URIS system has secured FDA clearance, positioning it within this robust market. For specific details on approval type and current market figures, direct sources such as FDA databases and industry reports are recommended.
It's worth noting that this certification positions Stimvia as only the third company in the world and the first in Europe with MDR (Medical Device Regulation) approval for both its eTNM and minimally invasive PTNS methods. Clinical studies show URIS achieves significant symptom relief in over 90% of patients, with a great safety profile without serious adverse events.
The URIS system's entry into the market comes at a time when there is a growing demand for non-drug options for patients who do not tolerate or respond well to medications. The total direct and indirect costs of OAB treatment in the US and Europe exceed 117 billion USD per year, yet many patients still lack effective care.
Stimvia was chosen from over 70,000 science and tech startups across more than 120 countries and regions to be part of the 2024/25 cohort at Endless Frontier Labs. The company successfully completed the nine-month accelerator, further solidifying its position in the global MedTech landscape.
As we move forward, it will be interesting to see how Stimvia's URIS system impacts the OAB treatment market and contributes to the growing trend of non-invasive, drug-free solutions in healthcare.
- The focus of Stimvia, a Czech Republic-based company, is on digital health, as they have developed the URIS system – a non-invasive neuromodulation device for treating Overactive Bladder (OAB) – which falls under the health-and-wellness category.
- In the world of medical plastics, Stimvia's URIS system employs a proprietary method known as eTNM (peroneal transcutaneous electrical nerve stimulation) for delivering targeted neurostimulation, potentially revolutionizing therapies-and-treatments for medical-conditions like OAB.
- The success of Stimvia, as demonstrated by their securement of FDA clearance and completion of the Endless Frontier Labs program, signifies a significant step in the science of neuromodulation, contributing to advancements in the wearable medical device market and the pursuit of non-drug options for medical-conditions like OAB.
